James F Sumowski1, Victoria M Leavitt2. 1. Neuropsychology and Neuroscience, Kessler Foundation, West Orange, NJ; Department of Physical Medicine and Rehabilitation, Rutgers, New Jersey Medical School, Newark, NJ. Electronic address: jsumowski@kesslerfoundation.org. 2. Manhattan Memory Center, New York, NY.
Abstract
OBJECTIVES: To investigate whether (1) resting body temperature is elevated in patients with relapsing-remitting multiple sclerosis (RRMS) relative to healthy individuals and patients with secondary progressive multiple sclerosis (SPMS), and (2) warmer body temperature is linked to worse fatigue in patients with RRMS. DESIGN: Cross-sectional study. SETTING: Climate-controlled laboratory (∼22°C) within a nonprofit medical rehabilitation research center. PARTICIPANTS: Patients with RRMS (n=50), matched healthy controls (n=40), and patients with SPMS (n=22). INTERVENTION: Not applicable. MAIN OUTCOME MEASURES: Body temperature was measured with an aural infrared thermometer (normative body temperature for this thermometer, 36.75°C), and differences were compared across patients with RRMS and SPMS and healthy persons. Patients with RRMS completed measures of general fatigue (Fatigue Severity Scale [FSS]), as well as physical and cognitive fatigue (Modified Fatigue Impact Scale [MFIS]). RESULTS: There was a large effect of group (P<.001, ηp(2)=.132) whereby body temperature was higher in patients with RRMS (37.04°±.27°C) relative to healthy controls (36.83°±.33°C; P=.009) and patients with SPMS (36.75°±.39°C; P=.001). Warmer body temperature in patients with RRMS was associated with worse general fatigue (FSS; rp=.315, P=.028) and physical fatigue (physical fatigue subscale of the MFIS; rp=.318, P=.026), but not cognitive fatigue (cognitive fatigue subscale of the MIFS; rp=-.017, P=.909). CONCLUSIONS: These are the first-ever demonstrations that body temperature is elevated endogenously in patients with RRMS and linked to worse fatigue. We discuss these findings in the context of failed treatments for fatigue in RRMS, including several failed randomized controlled trials (RCTs) of stimulants (modafinil). In contrast, our findings may help explain how RCTs of cooling garments and antipyretics (aspirin) have effectively reduced MS fatigue, and encourage further research on cooling/antipyretic treatments of fatigue in RRMS.
OBJECTIVES: To investigate whether (1) resting body temperature is elevated in patients with relapsing-remitting multiple sclerosis (RRMS) relative to healthy individuals and patients with secondary progressive multiple sclerosis (SPMS), and (2) warmer body temperature is linked to worse fatigue in patients with RRMS. DESIGN: Cross-sectional study. SETTING: Climate-controlled laboratory (∼22°C) within a nonprofit medical rehabilitation research center. PARTICIPANTS: Patients with RRMS (n=50), matched healthy controls (n=40), and patients with SPMS (n=22). INTERVENTION: Not applicable. MAIN OUTCOME MEASURES: Body temperature was measured with an aural infrared thermometer (normative body temperature for this thermometer, 36.75°C), and differences were compared across patients with RRMS and SPMS and healthy persons. Patients with RRMS completed measures of general fatigue (Fatigue Severity Scale [FSS]), as well as physical and cognitive fatigue (Modified Fatigue Impact Scale [MFIS]). RESULTS: There was a large effect of group (P<.001, ηp(2)=.132) whereby body temperature was higher in patients with RRMS (37.04°±.27°C) relative to healthy controls (36.83°±.33°C; P=.009) and patients with SPMS (36.75°±.39°C; P=.001). Warmer body temperature in patients with RRMS was associated with worse general fatigue (FSS; rp=.315, P=.028) and physical fatigue (physical fatigue subscale of the MFIS; rp=.318, P=.026), but not cognitive fatigue (cognitive fatigue subscale of the MIFS; rp=-.017, P=.909). CONCLUSIONS: These are the first-ever demonstrations that body temperature is elevated endogenously in patients with RRMS and linked to worse fatigue. We discuss these findings in the context of failed treatments for fatigue in RRMS, including several failed randomized controlled trials (RCTs) of stimulants (modafinil). In contrast, our findings may help explain how RCTs of cooling garments and antipyretics (aspirin) have effectively reduced MS fatigue, and encourage further research on cooling/antipyretic treatments of fatigue in RRMS.
Authors: D M Wingerchuk; E E Benarroch; P C O'Brien; B M Keegan; C F Lucchinetti; J H Noseworthy; B G Weinshenker; M Rodriguez Journal: Neurology Date: 2005-04-12 Impact factor: 9.910
Authors: B Stankoff; E Waubant; C Confavreux; G Edan; M Debouverie; L Rumbach; T Moreau; J Pelletier; C Lubetzki; M Clanet Journal: Neurology Date: 2005-04-12 Impact factor: 9.910
Authors: J M Chamberlain; T E Terndrup; D T Alexander; F A Silverstone; G Wolf-Klein; R O'Donnell; J Grandner Journal: Ann Emerg Med Date: 1995-01 Impact factor: 5.721
Authors: Steven R Schwid; Mary D Petrie; Ronald Murray; Jennifer Leitch; James Bowen; Alan Alquist; Richard Pelligrino; Adam Roberts; Judith Harper-Bennie; Maria Dawn Milan; Raul Guisado; Bernadette Luna; Leslie Montgomery; Richard Lamparter; Yu-Tsuan Ku; Hank Lee; Danielle Goldwater; Gary Cutter; Bruce Webbon Journal: Neurology Date: 2003-06-24 Impact factor: 9.910
Authors: L Kappos; D Moeri; E W Radue; A Schoetzau; K Schweikert; F Barkhof; D Miller; C R Guttmann; H L Weiner; C Gasperini; M Filippi Journal: Lancet Date: 1999-03-20 Impact factor: 79.321
Authors: Ashley N Frohman; Darin T Okuda; Shin Beh; Katherine Treadaway; Caroline Mooi; Scott L Davis; Anjali Shah; Teresa C Frohman; Elliot M Frohman Journal: Ann Clin Transl Neurol Date: 2015-06-26 Impact factor: 4.511